/stocks — the workspaceLOADING
All PROK SEC filings, by type → · Earnings date & implied move · Search inside filings
PROKIDNEY CORP. (PROK) is a biological products, (no diagnostic substances) company. 2 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-09 from PROK's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind PROK’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from PROK’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on PROK plus an auto-SWOT — built from PROK's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate PROK using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has PROK been issuing shares? Offering history →
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No lawmaker has disclosed a trade in PROK under the STOCK Act.
Projected from PROK's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentPROK files or announces.
PROK has sold off after 6 of its last 8 earnings reports.
Each figure is one earnings reaction — how much PROK moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
PROK has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+20.4% and -8.5%).
A more typical earnings reaction has been approximately ±4.4%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-10 | -1.8% |
| 2026-05-15 | -5.8% |
| 2026-03-18 | -8.5% |
| 2025-11-10 | -3.1% |
| 2025-08-12 | +5.1% |
| 2025-05-12 | +20.4% |
| 2025-03-17 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -1.4% |
| 2024-11-12 | -3.7% |
No tracked institution reported a position in PROK in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IWM iShares Russell 2000 ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Of 1 sale in the last ~6 months, 0 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 1 was filed without it.
| Pereira Brian JGDirector | SELL | $1.1M | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Head office: Winston-Salem, North Carolina, United States · the company’s charter and its head office are in different states.
EDGAR’s company directory says Cayman Islands. We show the company’s own most recent filing. The directory is a separate record, and the two can differ in either direction: a directory entry can change before the next filing shows a reincorporation, or go on showing a jurisdiction the company has left.
Source: the cover page of PROKIDNEY CORP.’s 10-Q filed 2026-08-10, on EDGAR. Filings checked 2026-10-20. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works